Your browser is no longer supported. Please, upgrade your browser.
MediciNova, Inc.
Index- P/E- EPS (ttm)-0.29 Insider Own7.72% Shs Outstand44.64M Perf Week4.20%
Market Cap270.17M Forward P/E- EPS next Y-0.34 Insider Trans-0.03% Shs Float41.46M Perf Month3.47%
Income-12.90M PEG- EPS next Q-0.09 Inst Own21.90% Short Float7.00% Perf Quarter11.40%
Sales- P/S- EPS this Y16.00% Inst Trans0.17% Short Ratio14.18 Perf Half Y3.47%
Book/sh1.65 P/B3.61 EPS next Y0.00% ROA-16.60% Target Price- Perf Year-7.45%
Cash/sh1.36 P/C4.38 EPS next 5Y20.00% ROE-17.60% 52W Range2.79 - 13.25 Perf YTD13.31%
Dividend- P/FCF- EPS past 5Y4.70% ROI- 52W High-55.02% Beta1.52
Dividend %- Quick Ratio34.70 Sales past 5Y- Gross Margin- 52W Low113.62% ATR0.24
Employees8 Current Ratio34.70 Sales Q/Q- Oper. Margin- RSI (14)61.76 Volatility4.66% 3.74%
OptionableYes Debt/Eq0.00 EPS Q/Q-51.20% Profit Margin- Rel Volume1.90 Prev Close5.79
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume204.59K Price5.96
Recom1.50 SMA208.15% SMA502.27% SMA2005.54% Volume388,066 Change2.94%
Mar-25-19Resumed B. Riley FBR Buy $22
Mar-28-18Initiated B. Riley FBR, Inc. Buy $22
Apr-18-17Initiated Credit Suisse Outperform
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
May-15-08Initiated Rodman & Renshaw Mkt Outperform $9
Jul-09-07Initiated Punk, Ziegel & Co Buy $22
Jan-18-21 06:00PM  
Jan-11-21 09:30PM  
Dec-29-20 06:30AM  
Dec-15-20 06:30AM  
Nov-30-20 05:38PM  
Nov-25-20 06:30AM  
Nov-24-20 06:30AM  
Nov-12-20 10:00PM  
Oct-30-20 06:05AM  
Oct-26-20 11:47AM  
Oct-22-20 06:30AM  
Oct-21-20 06:30AM  
Oct-13-20 06:30AM  
Sep-24-20 09:24AM  
Sep-23-20 10:37AM  
Sep-11-20 06:30AM  
Sep-02-20 11:23AM  
Sep-01-20 08:32AM  
Aug-06-20 06:30AM  
Aug-04-20 07:40AM  
Jul-28-20 08:13AM  
Jul-27-20 01:09PM  
Jul-20-20 06:30AM  
Jul-02-20 05:47AM  
Jul-01-20 06:30AM  
Jun-26-20 08:28AM  
Jun-25-20 07:00PM  
Jun-24-20 08:07AM  
Jun-23-20 07:00PM  
Jun-12-20 12:31PM  
May-01-20 11:30AM  
Apr-27-20 10:20AM  
Apr-20-20 07:00PM  
Apr-14-20 09:20AM  
Apr-08-20 07:53AM  
Mar-12-20 06:40AM  
Mar-09-20 07:00PM  
Feb-27-20 07:23AM  
Feb-25-20 08:15AM  
Feb-17-20 06:00PM  
Jan-28-20 07:12AM  
Jan-27-20 06:00PM  
Dec-04-19 06:00PM  
Nov-18-19 12:57PM  
Nov-06-19 01:50PM  
Oct-30-19 07:00PM  
Oct-28-19 06:00AM  
Oct-23-19 06:00AM  
Oct-07-19 07:00PM  
Sep-30-19 07:00PM  
Sep-19-19 03:48PM  
Sep-11-19 07:00PM  
Aug-29-19 07:00PM  
Aug-14-19 10:30AM  
Jul-30-19 07:00PM  
Jul-29-19 07:00PM  
Jul-24-19 11:00PM  
Jul-18-19 04:00PM  
Jul-11-19 07:00PM  
Jun-12-19 07:00PM  
Jun-05-19 07:00PM  
May-16-19 01:14PM  
May-15-19 07:00PM  
May-09-19 10:00AM  
May-08-19 07:23AM  
May-07-19 07:00PM  
Apr-24-19 08:09AM  
Apr-23-19 07:00PM  
Apr-16-19 08:10AM  
Apr-15-19 07:00PM  
Apr-08-19 09:45AM  
Apr-03-19 07:00PM  
Apr-01-19 07:00PM  
Mar-24-19 07:00PM  
Mar-05-19 06:51PM  
Feb-28-19 06:00PM  
Feb-20-19 10:00AM  
Feb-12-19 01:30PM  
Jan-21-19 06:00PM  
Jan-09-19 07:39AM  
Jan-08-19 06:00PM  
Jan-07-19 06:00PM  
Dec-12-18 10:06AM  
Oct-31-18 10:00AM  
Oct-05-18 08:35AM  
Oct-04-18 07:00PM  
Sep-28-18 09:45AM  
Sep-25-18 07:00PM  
Sep-18-18 07:00PM  
Sep-04-18 07:00PM  
Aug-29-18 05:00PM  
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nagao HidekiDirectorSep 15Sale5.781,0005,78015,000Sep 16 04:32 PM
Nagao HidekiDirectorAug 06Option Exercise2.5815,00038,70016,000Aug 07 08:53 PM
Matsuda KazukoChief Medical OfficerJun 12Option Exercise5.1320,000102,600160,192Jun 15 05:02 PM
Matsuda KazukoChief Medical OfficerApr 08Option Exercise2.5428,44672,253140,192Apr 13 09:42 PM
IWAKI YUICHIPresident and CEOApr 08Option Exercise2.5460,417153,459841,100Apr 13 09:40 PM
Matsuda KazukoChief Medical OfficerMar 13Buy3.622,0007,240111,476Mar 13 05:53 PM
IWAKI YUICHIPresident and CEOMar 12Buy3.1020,00062,000780,683Mar 12 06:39 PM